Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 7/20 | 0.61 |
| ▸ | ROS1 | P08922 | 6/20 | 0.61 |
| ▸ | EGFR | P00533 | 13/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26906951 | 1.00 | ALK (0.61) | ALKROS1EGFRLRRK2 | |
| SCHEMBL27114503 | 1.00 | ALK (0.61) | ALKROS1EGFRLRRK2 | |
| SCHEMBL29904636 | 0.86 | EGFR (0.58) | ALKROS1EGFR | |
| SCHEMBL26907011 | 0.85 | ALK (0.64) | ALKROS1EGFRLRRK2 | |
| SCHEMBL29904627 | 0.85 | ALK (0.64) | ALKROS1EGFRLRRK2 | |
| SCHEMBL29904648 | 0.83 | ROS1 (0.68) | ALKROS1EGFRLRRK2 | |
| SCHEMBL26906566 | 0.83 | ROS1 (0.68) | ALKROS1EGFRLRRK2 | |
| SCHEMBL27076036 | 0.77 | EGFR (0.74) | ALKEGFRLRRK2 | |
| SCHEMBL27076049 | 0.77 | EGFR (0.51) | ALKROS1EGFRLRRK2 | |
| SCHEMBL26906751 | 0.76 | EGFR (0.58) | ALKROS1EGFRLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022211573-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 테라펙스 | 2022-10-06 | — | — | WO | claimed |
| WO-2022211573-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 테라펙스 | 2022-10-06 | — | — | WO | disclosed |